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A B S T R A C T
Heme-containing peroxidases are frequently used in medical applications. However, these enzymes are
still extracted from their native source, which leads to inadequate yields and a mixture of isoenzymes
differing in glycosylation which limits subsequent enzyme applications. Thus, recombinant production of
these enzymes in Escherichia coli is a reasonable alternative. Even though production yields are high, the
product is frequently found as protein aggregates called inclusion bodies (IBs). These IBs have to be
solubilized and laboriously refolded to obtain active enzyme. Unfortunately, refolding yields are still very
low making the recombinant production of these enzymes in E. coli not competitive.
Motivated by the high importance of that enzyme class, this review aims at providing a comprehensive
summary of state-of-the-art strategies to obtain active peroxidases from IBs. Additionally, various
refolding techniques, which have not yet been used for this enzyme class, are discussed to show
alternative and potentially more efﬁcient ways to obtain active peroxidases from E. coli.
ã 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1.1. Classiﬁcation of heme-containing peroxidases
Heme-containing peroxidases are classiﬁed in four indepen-
dently evolved superfamilies, namely i) peroxidase-catalases, ii)
peroxidase-cyclooxygenases, iii) peroxidase-chlorite dismutases,
and iv) peroxidase-peroxygenases (Fig. 1). This denomination
reﬂects the characteristic enzymatic activities rather than the
origin of the enzymes [1]. Due to their wide variety of applications,
this review will mainly focus on members of the peroxidase-
catalase superfamily (Fig. 1).
1.2. Peroxidase-catalase superfamily
The peroxidase-catalase superfamily, formally known as the
superfamily of bacterial, fungal and plant peroxidases [2], is
subdivided into three families. Family I is the most divergent one
containing intracellular, peroxisomal and extracellular eukaryotic
peroxidases as well as cytochrome c peroxidase [1]. Family II
houses fungal peroxidases, which are mainly ligninolytic perox-
idases [3–9]. These enzymes are produced by fungi in response to
nutrient depletion [10,11]. Family III contains peroxidases from
plants, with the well-known representative horseradish peroxi-
dase (HRP). Amongst other physiological processes, plant perox-
idases participate in ligniﬁcation, the plant defense mechanism
and indole-3-acetic acid (IAA) metabolism [12–15].
1.3. Applications of peroxidase-catalases
Peroxidase-catalases are versatile enzymes frequently used in
various industrial and medical applications. They oxidize aromatic
compounds, the main pollutants in industrial waste water, to
phenoxy radicals, that form aggregates with reduced solubility
[16–18]. Resulting precipitates can be easily removed by sedimen-
tation or ﬁltration [16,19]. Peroxidase-catalases are also used in
biofuel production, where lignin is broken down by Family II
peroxidases to simple sugars. These sugars are then fermented intoFig. 1. Overview of the four heme peroxidase superfamilies. Superfamilies and
families shown in dashed grey boxes are not discussed in detail in this review.biofuel [17,20,21]. In biosensors these enzymes are used in
combination with a transducer to produce an electrical signal,
which is proportional to the concentration of the detected
chemical [14]. An application of high medical interest is the use
of peroxidase-catalases for targeted cancer treatment. By conju-
gation to tumor-speciﬁc antibodies, the enzymes are delivered
directly to the tumor, where an inactive prodrug is then oxidized to
a toxin. A prominent example for this kind of application is the
enzyme HRP (Family III) and the prodrug IAA [13,22–25]. However,
for applications in biosensors and medicine, enzyme glycosylation
plays a crucial role. In biosensors enzyme glycosylation can impede
electron transfer, as it may reduce the proximity of the active site of
the enzyme to the transducer [17]. In medical applications not only
the conjugation to antibodies is complicated by the presence of
heterogeneous surface glycans, but also the human body may show
immune responses to glycans of non-human origin [26]. Thus, the
issue of surface glycosylation must be considered once peroxidase-
catalases are recombinantly produced. Furthermore, following
Quality by Design guidelines, well-deﬁned enzyme preparations
rather than mixtures of isoenzymes derived from plant material
are required. Hence, it is highly desirable to produce these
enzymes recombinantly. However, as shown in Table 1 the
majority of commercially available enzymes still originate from
their native sources. Interestingly, some of the enzymes are not
commercially available at all. Only one recombinant enzyme,
offered for an extremely high price, is on the market, indicating
that the recombinant production of these enzymes is not straight-
forward.
1.4. Recombinant production of peroxidase-catalases
Amongst the studied expression hosts for the recombinant
production of peroxidase-catalases were mammalian cells, insect
cells, different yeasts and E. coli. Each of these hosts was
characterized by several advantages and disadvantages (Table 2).
As shown in Table 2, high production yields can be achieved in
yeast and E. coli. However, yeast has the tendency of hyper-
glycosylating recombinant glycoproteins, which impedes subse-
quent downstream processing and limits enzyme applications
[26,35]. This strongly argues for the recombinant production in E.
coli. Furthermore, up to 20-fold higher space-time-yields can be
achieved in E. coli compared to the yeast P. pastoris (own
unpublished data for HRP isoenzyme C1A). However, the presence
of disulﬁde bonds and the heme group in the active site of
peroxidase-catalases causes the formation of insoluble inclusion
bodies (IBs) rather than active enzyme. The alternative expression
in the periplasm of E. coli only gives low yields [30,38,39], which is
why the production of this enzyme family as IBs, followed by
refolding, is inevitable.
1.5. Inclusion bodies (IBs)
The formation of IBs highly depends on the protein itself.
Charge distribution, cysteines and hydrophobic regions usually
have a severe impact on protein aggregation. Next to protein
characteristics, strong promoter systems, high temperature and
translational rates as well as the missing oxidative environment of
the bacterial cytoplasm favor IB formation [40–42]. However, IB
Table 1
Peroxidase-catalases discussed in this review.
Peroxidase-Catalase Family Supplier; price for 10 mg Source Refs.
Lignin peroxidase (LiP) II Sigma; 88.6 s fungi [3–5]
Manganese peroxidase (MnP) II Sigma; 78.5 s fungi [6,7,27]
Versatile peroxidase (VP) II Sigma; 76.6 s fungi [8,9]
Horseradish peroxidase (HRP) III Sigma; 95.3 s plant [28–30]
Soybean peroxidase (SBP) III Bio-Research Products; ca. 48 s plant
Tobacco peroxidase (TOP) III MyBioSource; ca. 15,000 s E. coli [31,32]
Turnip acidic peroxidase (BnPA) III – [12]
Cationic cell wall peroxidase (CWPO_C) III – [33]
Barley grain peroxidase (BP 1) III – [34]
Arabidopsis thaliana peroxidase (ATP N) III – [34]
Table 2
Advantages and disadvantages of expression hosts for the recombinant production of peroxidase-catalases.
Organism Advantages Disadvantages Refs.
native source (ﬁlamentous fungi, plant) native glycosylation low yield [26,35]
costly production
isoenzyme mixtures
insect cells human-like glycosylation low yield [22,26,36]
mammalian cells costly production
yeast high yield heterogeneous [22,26,35,36]
cheap production hyperglycosylation
high cell density cultivations
extracellular production
E. coli high yield IB production [22,26,35–37]
cheap production low refolding yields
high cell density cultivations no glycosylation
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production strategy. Besides low cultivation costs and rapid
growth, the production of the target product as IBs bears several
advantages, as i) more than 30% of the overall cellular protein can
be expressed as IBs, ii) the protein is protected from proteolytic
degradation, iii) IBs can be easily separated from cell debris due to
their difference in density, and iv) IBs contain up to 95% of the
recombinant protein and only small amounts of contaminants
(Table 3) [37,42–44]. Although this review will not focus on IB
production, it should be mentioned, that the quality of IBs
signiﬁcantly inﬂuences the solubilization and refolding yield. The
presence of secondary and tertiary structures in IBs can be
enhanced by growth conditions [45] and supplementation with
cofactors or precursors [46–48].Table 3
Composition of a typical IB.
IB component Building block 
target protein unfolded 
partly folded
native folded
proteolytic fragments
non-protein components phospholipids 
nucleic acids
lipopolysaccharides
host cell proteins outer membrane proteins 
proteins of the folding machinery
ribosomal subunit proteinsIn the following chapters we will discuss the processing of
peroxidase IBs with the main focus on the superfamily of
peroxidase-catalases.
2. Peroxidase IB processing: state of the art
To gain active product from IBs, wash, solubilization and
refolding is inevitable [37,56]. A typical IB processing workﬂow,
that describes an established platform strategy for all kinds of
proteins, is shown in Fig. 2.
However, the recovery of active peroxidases from IBs is not
efﬁcient to date, which is why the only recombinant enzyme on the
market is offered for a tremendous price (Table 1). In the following
chapters we will summarize the current IB processing stepsContent [%] Refs.
<95% [49–51]
>5% [42,49,50,52–54]
[41,49,50,53,55]
Fig. 2. General platform strategy of IB processing.
78 B. Eggenreich et al. / Biotechnology Reports 10 (2016) 75–83applied for peroxidases, that actually correspond to the platform
strategy depicted in Fig. 2, and elaborate on potential pitfalls
connected to this enzyme class.
2.1. IB recovery
Cell disruption methods for IB recovery are mostly sonication,
lysozyme treatment and high pressure homogenization. For large
scale processes, homogenization is the most feasible method. As
shown in recent studies, there is a negligible portion of protein lost
from IBs and protein activity is not compromised throughout the
homogenization process [57]. The typical buffer for peroxidase IB
recovery actually describes a common buffer for all kinds of
proteins (Table 4). Dithiothreitol (DTT) is usually added to prevent
oxidation of cytoplasmatic proteins. Ethylenediaminetetraacetic
acid (EDTA) is used to bind Ca2+ and Mg2+ and thus cross-bridge
adjcent lipopolysaccharides [58–60]. Hence, the permeability of
membranes is increased. Also chaotropes can be used, however in
high concentration, like urea (10 M), they are not easy to handle
and the target protein could already get solubilized during
disruption. Furthermore, Triton X (1%), Phenylmethylsulfonyl
ﬂuoride (0.5–10 mM) and RNase (0.1 mg/ml) can be added
[5,6,27,29].
2.2. IB wash
To remove impurities on the surface of IBs, a wash step is
recommended [42,61]. For peroxidases the reported washTable 4
Typical buffer components and concentration ranges at different IB processing
steps.
Buffer components IB recovery IB wash IB solubilization
Tris HCl 10–50 mM 20–50 mM 20–100 mM
pH 8.0 8.0 or 8.5 8.0 or 8.5
DDT 2–10 mM 1–
10 mM
1–30 mM
EDTA  1–10 mM 1–2 mM 1–2 mM
urea 2 M 6–8 M
guanidine hydrochloride
(GndHCl)
6 M
NaCl  2 M
lysozyme  2 mg/ml
DNase  0.1 mg/ml
Triton X  100 1–3%procedure is in accordance to the generally implemented protocols
for IBs. The cell debris/IB pellet is washed two to three times to
obtain an IB purity of 50–95% [3,4,27,29,31,32]. In case the E. coli
strain is not deﬁcient of it, a good wash procedure leads to the
removal of OmpT protease, which is active in 4–8 M urea buffer and
can thus degrade the protein of interest during wash and
solubilization [34]. The use of low concentrated detergents, such
as Triton X-100, and denaturing agents, such as urea (Table 4), can
lead to solubilization of outer membrane proteins and therefore to
higher IB purity. However, also IBs can already get solubilized and
detergents are difﬁcult to remove in the subsequent downstream
process [8,62]. In general, the advantage of a higher purity has to be
weighed against buffer and time consumption.
2.3. IB solubilization
Succeeding wash, solubilization employing urea as chaotropic
agent is usually performed (Table 4). Reducing agents like DTT and
b-mercaptoethanol are added to keep cysteine residues in a
reduced state and hinder the formation of intra- and intermolecu-
lar disulﬁde bonds [42,63]. Since DTT can react with oxygen to
hydrogen peroxide and is thus reduced, nitrogen purging through
the solubilization medium is recommended [6,32]. Chelating
agents, such as EDTA, are commonly used to reduce metal-
catalyzed air oxidation of cysteines [42]. As for temperature, 4 C or
room temperature is mostly chosen. Solubilization times of up to
6 h were reported [6,27]. We recommend not prolonging the
solubilization process needlessly since DTT is unstable and
undergoes oxidation. Consequently, cysteines are no longer kept
in the reduced state and undesired disulﬁde bonds might be
formed [63].
2.4. Refolding
The ﬁrst three processing steps of peroxidase IBs, namely
recovery, wash and solubilization, correspond to the commonly
used platform technology applied on all kinds of proteins (Fig. 2).
However, since peroxidases share the speciﬁc feature of having Ca2
+ and heme incorporated in their active sites, it is obvious that this
must be especially considered in IB refolding.
2.4.1. Refolding buffer
A typical refolding buffer for peroxidases is shown in Table 5.
The refolding buffer usually contains intermediate concen-
trations of denaturants (e.g. GndHCl, urea). On the one hand these
concentrations keep the protein soluble, but on the other hand
these concentrations are low enough to allow refolding [64]. In
case of peroxidases, 0.15–2 M denaturant is usually used.
Thiol agents such as DTT/GSSG, oxidized/reduced glutathione
(GSSG/GSH), cysteine/cystine or cysteamine/cystamine are added
so that correct disulﬁde bonds, crucial for biological activity, can beTable 5
Typical IB refolding buffer for peroxidases.
Buffer component Concentration
Tris HCl 20–50 mM
GndHCl 0.6 M
urea 0.15–2 M
GSSG 0.35–0.7 mM
DDT 0.044–0.1 mM
pH 8.0–9.5
glycerol 4–10%
CaCl2 2–5 mM
heme 5–20 mM
enzyme 8–700 mg/ml
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usually differs from 1:1 to 10:1 [42,61,66,67].
Another critical factor for disulﬁde bond formation is the pH
value. Thiols are only active as thiolate anions and due to their pKa
values from 8.0 to 9.5, they are most reactive under alkaline
conditions [66,68,69]. When disulﬁde bonds are correctly formed,
one should always take into account that free thiols are capable of
altering existing disulﬁde bridges. This phenomenon is known as
disulﬁde scrambling [69]. Thus, after refolding at a basic pH, a
buffer exchange to a neutral or slightly acid pH value should be
performed, if this agrees with protein properties [63,69].
To avoid protein aggregation, refolding additives can be added.
In previous studies, glycerol was found to act as stabilizer for
peroxidases [6,12,28,30,32]. Other common refolding additives,
which are usually used in refolding buffers, but have not been
reported for peroxidases yet, are summarized in Supplementary
Table 1.
As mentioned above, CaCl2 and heme have to be added to the
refolding buffer to obtain active peroxidases. Ca2+ ions are required
to form a protein structure which is capable of incorporating heme
[29]. A lot of studies were performed to investigate the inﬂuence of
Ca2+ on stability and activity of fungal and plant peroxidases
[29,70–74]. HRP and MnP show an absolute dependence on Ca2+ for
proper folding [6,29]. In case of HRP, the loss of one Ca2+ leads to a
50% reduction of activity as well as a decrease in stability [29]. For
MnP, the loss of Ca2+ leads to a structural loss and thus a loss of
heme. In several studies EDTA in concentrations between 0.05 
0.1 mM was added to the refolding buffer of peroxidases. However,
we strongly advise against using EDTA in any buffer subsequent toFig. 3. Simpliﬁed demonstration of a screening platform of refolding buffers and conditi
constant (e.g. molarity of the Tris HCl buffer, glycerol, CaCl2), whilst others are varied (e.g
refolding additives can be determined.solubilization, because it binds Ca2+ and thus decreases the
refolding yield [34].
Heme leads to the active holoenzyme and must be supple-
mented during IB refolding. However, heme is hydrophobic and
non-speciﬁcally adsorbs to the surface of hydrophobic amino acids
[30]. Furthermore, free heme can react with oxygen and reducing
thiols to oxidative species that alter amino acid residues in the
polypeptide chain and therefore decrease the refolding yield [32].
Thus, the time point of heme-addition is crucial [32]. In fact,
successful heme incorporation is dependent on the correctly
folded structure of the apoenzyme. Another important fact to be
considered is that heme in higher concentrations aggregates very
easily [75]. Therefore our recommendation is to supplement heme
in not much higher than equimolar amounts when the apoenzyme
is correctly folded.
As shown in Table 5, a typical refolding buffer for peroxidases
contains several components. To ﬁnd the best refolding buffer
mixture for a speciﬁc enzyme, we recommend using multivariate
screening experiments where some parameters are kept constant
(e.g. molarity of the Tris HCl buffer, glycerol, CaCl2), whilst others
are varied (e.g. heme, pH, protein concentration). As depicted in
Fig. 3 we recommend using colorimetric assays in 96 well
plates to keep buffer and enzyme consumption at a minimum
and to be able to screen many conditions at the same time
[3,4,8,27,29,32,33,77,78].
Artiﬁcial Chaperone Assisted refolding should be mentioned at
this point. This method mimics bacterial chaperons by a
combination of denaturation by a detergent, e.g. SDS, followed
by a dilution with cyclodextrine that slowly strips the detergent.ons for peroxidases. In small scale, namely 96 well plates, some parameters are kept
. heme, pH, protein concentration). Via colorimetric assays the best concentration of
80 B. Eggenreich et al. / Biotechnology Reports 10 (2016) 75–83This method was reported to be highly beneﬁcial to avoid protein
aggregation [76], but has not been applied for peroxidase IB
refolding yet.
2.4.2. Refolding techniques
To date, peroxidases are still refolded using the dilution
method, which in fact describes a platform technique for all types
of proteins. In the dilution method solubilized protein is directly
added into the refolding medium. Consequently, the denaturant
concentration is rapidly reduced. In case the protein concentration
is too high, this rapid reduction of denaturant causes protein
aggregation [37,42,49]. Hence, protein concentration has to be kept
at a minimum [44]. Excessive agitation during refolding can also
cause protein aggregation due to elevated shear and interfacial
stress [62]. The recently developed temperature leap tactic was
shown to improve refolding yields [37,79]. At low temperatures
aggregation is suppressed, but also folding. Hence, during the
initial phase of refolding, temperatures are kept low to reduce
aggregation, but a subsequent temperature jump enhances
refolding [37]. However, refolding yields achieved by the dilution
method are still very low for peroxidases except for TOP, where a
refolding yield of up to 85% was reported [32]. This is possibly the
reason why TOP is the only commercially available recombinant
peroxidase, even though the price is exceptionally high (Table 1). In
the latter study also on-column refolding by SEC was tested [32].
The principle of on-column refolding by SEC is, that denaturized
protein has a random coil conﬁguration and a large hydrodynamic
radius, and thus does not enter the pores of the beads [80]. When
the refolding medium is applied on the column, the concentration
of the denaturant is gradually decreased and the protein develops a
more compact structure, which is able to enter the pores. Inside the
pores the refolding process continues, with hardly any possibility
for the protein to aggregate [80]. To further reduce aggregation
urea/pH gradients can be introduced [81,82]. Aggregates, inter-
mediates, native protein and small weight denaturants are
separated by size, and so a puriﬁcation step is included in thisFig. 4. Typical IB processing of peroxidases. After IB production in shake ﬂasks or bioreact
with chaotropic agents. Then, solubilized IBs are refolded by dilution, a procedure where
SEC, as alternative, was recently performed with TOP [32].procedure [80]. Another advantage of the SEC-based refolding
method is that intermediates and aggregates can be recycled to the
column continuously to enhance the refolding yield [44]. On-
column refolding by SEC resulted in a refolding yield of 35% for TOP
[32].
Summarizing, in Fig. 4 we show the typical IB processing
strategy for peroxidases to date. However, except for TOP, refolding
yields for peroxidases are very low impeding the commercializa-
tion of recombinantly produced enzymes.
2.5. Potential alternative refolding techniques
As shown above, the typical IB processing strategy for
peroxidases corresponds to platform strategies commonly used
for all kinds of proteins. Only during the refolding step certain
enzyme speciﬁc features must be considered to obtain active
enzyme. However, current refolding techniques applied on
peroxidases only give refolding yields lower than 30%, except for
TOP. Thus, we will shortly describe other refolding techniques
which were successfully applied on other proteins and could be an
alternative also for peroxidases.
2.5.1. Pulse dilution, fed-batch refolding
In pulse dilution, a small amount of solubilized protein is added
to the refolding buffer in consecutive time intervals. Once the
protein is folded into its native state, no aggregation with
misfolded protein can occur. Thus, a reduction of buffer
consumption and a better refolding yield compared to the simple
dilution method was achieved [49]. In fed-batch refolding, the
denaturized protein is added at a constant low ﬂow rate to the
refolding buffer [83,84].
2.5.2. Dialysis
In dialysis, the solubilized protein is brought to equilibrium
with low denaturant-containing refolding buffer. Since the rapid
decrease of denaturant leads to aggregation (vide supra), a two-ors, biomass is harvested, followed by cell disruption. IBs are washed and solubilized
 the concentration of chaotropic agents is rapidly reduced. On-column refolding by
B. Eggenreich et al. / Biotechnology Reports 10 (2016) 75–83 81step dilution method was introduced where the denaturized
protein was brought to equilibrium with a higher concentration of
denaturant, before it was dialyzed against a lower concentration
[85].
2.5.3. Ion exchange chromatography (IEX)
In IEX, the solubilized protein adsorbs to the resin. By washing
with refolding buffer, either step-wise or gradually, refolding is
initiated [44,86]. Applying a dual gradient (pH and urea) during
wash allows optimizing for correct disulﬁde bond formation [87].
Also artiﬁcial chaperones can be added to the wash buffers and
applied in a controlled manner enhancing refolding [88].
2.5.4. Hydrophobic interaction chromatography (HIC)
In HIC, the column is equilibrated with refolding buffer
containing a high salt concentration, before the solubilized protein
is loaded. Refolding and subsequent elution are initiated by
decreasing the salt concentration in the wash buffer. Urea and
refolding additives, like glycerol, can be added to the buffer
allowing a high degree of freedom and control. This strategy has
already resulted in a more than 80% refolding yield before [89].
2.5.5. IMAC
If the target protein is His-tagged, IMAC can be used for
refolding, but also for puriﬁcation between solubilization and
refolding [12,28,30]. In general, the refolding protocol using IMAC
is straight-forward: the protein gets solubilized, immobilized onTable 6
Advantages and disadvantages of the different refolding techniques and recommendat
Technique Advantage Disadvantage 
Dilution  simple method  only low protein
can be used 
 high aggregation
 scale-up is probl
 high buffer cons
Pulse/fed-batch
dilution
 simple method  pulse/feed calcul
 high protein concentrations can be
used
knowledge about r
Dialysis  simple method  high aggregation
 time consuming
 protein loss in m
SEC  folding and puriﬁcation in one  possible aggregat
step  resin has to allow
 low aggregation
rate of denatured prote
 high protein protein and folding
concentrations can be used
IEX  folding and  careful optimiza
puriﬁcation in one step  high non- speciﬁ
refolding
 high protein concentrations can be
used
 aggregation is suppressed
HIC  folding and puriﬁcation in one step  strong hydropho
 aggregation is suppressed
IMAC  simple method  His-tag can inter
 puriﬁcation before  metal-ion leakag
folding
 low aggregation  reducing agents 
rate  interaction of im
active sitecolumn, a reduction of the chaotropic agent is applied for refolding,
which is followed by elution of the native protein [90,91].
Usually imidazole or lowering the pH of the elution buffer
detaches the target protein from the column [92]. However, we do
not recommend using IMAC for IB processing of peroxidases due to
several reasons:
 Imidazole competes with histidine amino acids in the heme
binding pocket and thus prevents heme incorporation. Hence, it
is absolutely necessary to remove imidazole to get active enzyme
and IMAC has to be followed by a careful desalting step, which
puts the beneﬁt of the His-tag in question [30].
 A puriﬁcation tag can interfere with the structure and function of
the tagged protein, and probably has to be removed [93].
 Since reducing agents in the solubilization buffer can reduce
metal-ions and thus damage the resin, special IMAC columns for
refolding have to be used [94].
 Leakage from the IMAC column has to be taken into account,
since the stability of the product can be affected by metal-ions
[94].
In Table 6 we summarize the advantages and disadvantages of
the different refolding techniques and give recommendations
based on our own experiences and the success and complexity of
the respective strategy described in literature. In general, we
recommend implementing pulse dilution or fed-batch refoldingions.
Recommendation Refs.
 concentrations [44,49,61,63,76]
+
 rate
ematic
umption
ation demands +++ [40,49,61,63]
efolding kinetics
 rate – [62–64,76]
embrane
ion leads to column clogging or uneven ﬂow ++ [43,44,63]
 the separation
in, misfolded
 intermediates
tion required + [43,44,61,63]
c interactions with matrix can hinder
bic interaction prevents refolding + [43,44,63,89]
fere with folding – [30,43,44,61,94]
e
damage column
idazole with
82 B. Eggenreich et al. / Biotechnology Reports 10 (2016) 75–83for peroxidases since the aggregation rate can be minimized once
the refolding kinetics is known.
3. Final enzyme preparation
To gain a highly puriﬁed enzyme, several puriﬁcation steps are
performed after refolding. Usually, dialysis, IEX-chromatography
and polishing steps are applied, giving a highly pure enzyme
preparation [3,8,30,32]. A typical indicator for purity of perox-
idases is the RZ value (A Soret peak maximum/A 280 nm) which is
signiﬁcantly inﬂuenced by contaminants, heme occupancy and
aggregation. Aggregation leads to light scattering and contributes
to additional absorption at 280 nm [3,30]. With respect to
biochemical properties of refolded peroxidases, catalytic constants
were reported to be similar to the native enzymes. Sometimes,
even lower Km values were reported which was ascribed to better
accessibility of the active site due to missing glycosylation [12].
However, missing glycosylation can also reduce the thermal
stability of the enzyme [12].
4. Conclusions
Due to the wide variety of environmental, industrial and
medical applications of peroxidases, the demand for pure and
unglycosylated enzymes is increasing. E. coli as recombinant host
gives high product yields, but peroxidases are usually produced as
IBs, due to the presence of disulﬁde bonds and the cofactor heme.
In this review we summarize recent studies dealing with IB
processing of peroxidases. We shed light on the different steps of a
typical IB processing procedure, namely IB recovery, wash,
solubilization and refolding. We do not only describe refolding
buffer composition and common refolding techniques for this
enzyme class, but also discuss potential alternative strategies. This
review presents a comprehensive summary of current IB process-
ing studies of peroxidases and should serve as guideline and
inspiration for future studies.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.btre.2016.03.005.
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